Skip to main content
. 2018 Jun 15;41(8):369–378. doi: 10.1097/CJI.0000000000000231

FIGURE 3.

FIGURE 3

A, Survival of mice with SW1, B16 or TC1 tumors which had 4 (small tumor) or 8 mm (big tumor) diameters on the right side of the back when the 4 mAb combination was first injected; 3 weekly treatments. B, Tbx/Gata3 ratios for TLN and spleen cells 3 and 24 days after the first injection of 3 mAb with or without cisplatin. Naive (ie, not tumor-bearing) mice were injected subcutaneous with the 3 mAb combination and given cisplatin intraperitoneally; untreated tumor-bearing mice received control mAbs. C, Expression level of IFNγ for TLN and spleen cells 24 days after the first treatment. D, Percentages of CD69+, CD44+CD62l−, E7 tetramer+ and CD11b+Gr1+ spleen cells on day 24. IFN indicates interferon; mAb, monoclonal antibody; TLN, tumor-draining lymph nodes.